Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.
Ross, P J
Hawkins, Robert E
Seymour, M T
AffiliationSection of Medicine, Gastrointestinal Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.
MetadataShow full item record
AbstractThe aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (> or =70) in comparison to younger patients. 1080 patients were enrolled into three randomised controlled trials assessing fluorouracil-based combination chemotherapy. Patients received either a platinum-containing regimen (ECF, MCF), PVI 5-FU (protracted venous infusion of 5-fluorouracil)+/-mitomycin C (MMC), or FAMTX. Of the 1080 patients randomised, 257 (23.8%) were aged > or =70 years. There were no significant differences in the incidence of grades 3/4 toxicity between the two cohorts. Objective and symptomatic response rates, failure-free and overall survival were not significantly different. In a multivariate analysis, independent prognostic factors for survival were performance status and locally advanced disease, not age. Patients > or =70 years with OGC obtained similar benefits from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities.
CitationEfficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. 2006, 42 (7):827-34 Eur. J. Cancer
JournalEuropean Journal of Cancer
- Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
- Authors: Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T
- Issue date: 1999 Apr
- Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy.
- Authors: Lord SR, Hall PS, McShane P, Brown J, Seymour MT
- Issue date: 2010 Mar
- Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
- Authors: Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI
- Issue date: 2009 Feb
- Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
- Authors: Forshaw MJ, Gossage JA, Chrystal K, Cheong K, Atkinson S, Botha A, Harper PG, Mason RC
- Issue date: 2006 Dec
- A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
- Authors: Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M
- Issue date: 2002 Oct